title: Cardiac toxicity related to cancer treatment.
abstract: Cardiac toxicity is a dose-limiting toxicity that may occur during cancer treatment or several years after therapy ends. Cardiac toxicity may be caused by chemotherapy, biotherapy, and radiation therapy and may result in cardiomyopathy, congestive heart failure, dysrhythmias, and myocardial ischemia. The risk for developing cardiac toxicity varies based on type of treatment, patient age, presence of preexisting or concurrent heart disease, and concomitant treatment. Patients at high risk require careful evaluation and monitoring during and in the years following therapy to detect cardiac changes. Fortunately, cardioprotective agents and newer radiation therapy techniques decrease the risk for treatment-related cardiac toxicity. Oncology nurses can become more informed in the assessment of cardiac toxicity and can arm themselves with knowledge about early identification of symptoms as well as specific agents and treatments that increase risk for cardiac toxicity.
authors: vloerzel@mail.ucf.edu
authors: Victoria Wochna
authors: VW
authors: Loerzel
authors: Karen Hassey
authors: KH
authors: Dow
mesh_terms: D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001691:Biological Therapy / Q000009:adverse effects*; D002317:Cardiovascular Agents / Q000627:therapeutic use; D002648:Child; D006331:Heart Diseases / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control; D006801:Humans; D009369:Neoplasms / Q000628:therapy*; D024802:Nurse's Role; D009730:Nursing Assessment; D009859:Oncology Nursing; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects*; D011929:Razoxane / Q000627:therapeutic use; D012307:Risk Factors
chemical_list: D000970:Antineoplastic Agents; D002317:Cardiovascular Agents; D011929:Razoxane